**Core Concept**
Spironolactone is a potassium-sparing diuretic that acts as an aldosterone antagonist, thereby increasing renal potassium levels. Concomitant administration of certain medications can lead to hyperkalemia, a potentially life-threatening condition.

**Why the Correct Answer is Right**
Spironolactone should not be given with ACE inhibitors (angiotensin-converting enzyme inhibitors) because both classes of medications increase potassium levels in the body. ACE inhibitors block the conversion of angiotensin I to angiotensin II, leading to vasodilation and a decrease in aldosterone levels. However, this decrease in aldosterone levels results in decreased potassium excretion, which, when combined with spironolactone, can lead to severe hyperkalemia. This is particularly concerning in patients with pre-existing renal impairment or those taking other potassium-sparing medications.

**Why Each Wrong Option is Incorrect**
**Option A:** Chlorthiazide is a thiazide diuretic that increases sodium and chloride excretion, leading to a mild increase in potassium excretion. This effect is actually beneficial when combined with spironolactone, as it helps to counterbalance the potassium-sparing effects of the latter.

**Option B:** Beta blockers can be administered concomitantly with spironolactone without significant concern for hyperkalemia. Beta blockers primarily affect the heart rate and contractility, and do not have a direct impact on potassium levels.

**Option D:** Amlodipine is a calcium channel blocker that primarily affects vascular smooth muscle tone, leading to vasodilation. It does not have a significant impact on potassium levels and can be safely administered with spironolactone.

**Clinical Pearl / High-Yield Fact**
When administering spironolactone, it is essential to monitor potassium levels closely, especially in patients taking other potassium-sparing medications or those with pre-existing renal impairment. Regular monitoring and dose adjustments can help prevent hyperkalemia and ensure safe patient outcomes.

**✓ Correct Answer: C. ACE inhibitors**